RT Journal Article
SR Electronic
T1 Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.26.21262468
DO 10.1101/2021.08.26.21262468
A1 Tober-Lau, Pinkus
A1 Schwarz, Tatjana
A1 Vanshylla, Kanika
A1 Hillus, David
A1 Gruell, Henning
A1 ,
A1 Suttorp, Norbert
A1 Landgraf, Irmgard
A1 Kappert, Kai
A1 Seybold, Joachim
A1 Drosten, Christian
A1 Klein, Florian
A1 Kurth, Florian
A1 Corman, Victor Max
A1 Sander, Leif Erik
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.26.21262468.abstract
AB COVID-19 mRNA vaccine BNT162b2 is highly immunogenic and effective, but recent studies have indicated waning anti-SARS-CoV-2 immune responses over time. Increasing infection rates has led authorities in several countries to initiate booster campaigns for vulnerable populations, including the elderly. However, the durability of vaccine-induced immunity in the elderly is currently unknown. Here, we describe interim results of a prospective cohort study comparing immune responses in a cohort of vaccinated elderly persons to those in healthcare workers (HCW), measured six months after first immunisation with BNT162b2. Anti-SARS-CoV-2 S1-, full Spike- and RBD-IgG seropositivity rates and IgG levels at six months were significantly lower in the elderly compared to HCW. Serum neutralization of Delta VOC measured by pseudovirus neutralisation test was detectable in 43/71 (60.6%, 95%CI: 48.9-71.1) in the elderly cohort compared to 79/83 in the HCW cohort (95.2%, 95%CI: 88.3-98.1) at six months post vaccination. Consistent with the overall lower antibody levels, SARS-CoV-2-S1 T cell reactivity was reduced in the elderly compared to HCW (261.6 mIU/ml, IQR:141.5-828.6 vs 1198.0 mIU/ml, IQR: 593.9-2533.6, p<0.0001).Collectively, these findings suggest that the established two-dose vaccination regimen elicits less durable immune responses in the elderly compared to young adults. Given the recent surge in hospitalisations, even in countries with high vaccination rates such as Israel, the current data may support booster vaccinations of the elderly. Further studies to determine long-term effectiveness of COVID-19 vaccines in high-risk populations and the safety and effectiveness of additional boosters are needed.Competing Interest StatementVMC is named together with Euroimmun GmbH on a patent application filed recently regarding SARS-CoV-2 diagnostics via antibody testing. HG and FKl are named on a patent application regarding neutralising antibodies against SARS-related coronaviruses. All other authors declare no competing interests.Clinical TrialEudraCT-No. 2021-001512-28Funding StatementParts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance. This study was further supported by the German Ministry of Research through the projects VARIPath (01KI2021) to VMC, and NaFoUniMedCovid19-COVIM, FKZ: 01KX2021 to LES, FK, FKI, CD, and VMC. VMC is a participant in the BIH-Charite Clinician Scientist Program funded by the Charite - Universitaetsmedizin Berlin and BIH. Part of this work was funded by the German Ministry of Education and Research through projects VARIPath (01KI2021) to VMC and Deutsche Forschungsgemeinschaft (SFB-TR84 to NS and LES). The study was supported by a donation from Zalando SE to Charite - Universitaetsmedizin Berlin.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study participants were recruited in the EICOV, COVIMMUNIZE, and COVIM studies, three prospective cohort studies conducted under the auspices of Charite-Universitaetsmedizin Berlin, Germany, in accordance with the Declaration of Helsinki and Good Clinical Practice. EICOV and COVIMMUNIZE studies were approved by the local ethics committee of Charite-Universitaetsmedizin Berlin (EA4/244/20, EA4/245/20), and COVIM was approved by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and by the ethics committee of the state of Berlin (EudraCT-2021-001512-28). Written informed consent was obtained by all participants, according to local and national regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised raw immunogenicity data for tested samples and anonymised reactogenicity data can be obtained upon request. Requests will be reviewed and approved by the authors, collaborators, and the security department on the basis of scientific merit and absence of competing interests.